# A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee

> **NCT03956550** · PHASE2 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 259 (actual)

## Conditions studied

- Osteoarthritis of the Knee
- Pain

## Interventions

- **DRUG:** REGN5069
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT03956550
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-21
- **Primary completion:** 2020-05-01
- **Final completion:** 2020-10-29
- **Target enrollment:** 259 (ACTUAL)
- **Why stopped:** Regeneron has discontinued further clinical development of REGN5069, an antibody to GFRα3, which was previously being studied in osteoarthritis pain of the knee
- **Last updated:** 2021-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03956550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03956550, "A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03956550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*